|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed anti-microbial technology company Byotrol (LON:BYOT) has seen its share price decline by 13.66% to 2.06p (as of 13:50 BST) after the news that it expected to book an EBITDA loss of around £450,000 for the year ended 31st March. This is largely down to increase R&D and marketing costs as well as the impact of delayed regulatory approval in the US.
Chief executive David Traynor said: “Byotrol is continuing to progress well and all key strategic initiatives are performing to plan. We are very excited about the potential for the enlarged business including MSL and for the synergies that will be released from the combination in due course“.